Navigation Links
Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
Date:8/19/2013

OKLAHOMA CITY, Aug. 19, 2013 /PRNewswire/ -- Selexys Pharmaceuticals Corporation, a privately held biopharmaceutical company that is developing therapies to treat inflammatory and thrombotic diseases, today announced that enrollment has been initiated in SUSTAIN, a Phase II, multicenter, randomized, placebo-controlled, double-blind, 12-month study to assess safety and efficacy of the anti-P-selectin monoclonal antibody SelG1 with or without hydroxyurea therapy in sickle cell disease patients with sickle cell-related pain crises.

The SUSTAIN trial will randomize approximately 174 patients to receive high dose SelG1, low dose SelG1 or placebo in the presence or absence of hydroxyurea therapy, the current standard of treatment. The study will examine the effectiveness of SelG1 in reducing the rate of sickle cell-related pain crises in each active dose level as compared to placebo. The study will be conducted in approximately 60 centers throughout the U.S. Further information on this trial is available at clinicaltrials.gov (NCT01895361).

"With the limited therapies available to patients with sickle cell disease, this trial with a novel P-selectin inhibitor is particularly exciting. Not only does it have the potential to improve the clinical outcomes in patients, its effects may be additive or synergistic with those of hydroxyurea, the only drug currently approved by the FDA for treatment of complications due to sickle cell disease," stated Dr. Kenneth Ataga, Lead Investigator and Associate Professor of Medicine in the Division of Hematology/Oncology, University of North Carolina at Chapel Hill.

"Data from preclinical sickle cell disease models suggest that blockade of P-selectin effectively prevents the painful stoppage of circulation in small blood vessels called vasoocclusion and maintains patent
'/>"/>

SOURCE Selexys Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Selexys Pharmaceuticals Completes $23M Equity Financing and Signs Agreement With Global Pharmaceutical Company
2. Cadence Pharmaceuticals Comments on USPTOs Non-Final, Initial Office Action on Reexamination of Patent
3. Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
4. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
5. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
6. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
7. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
8. Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc.
9. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
10. AcelRx Pharmaceuticals Reports Second Quarter 2013 Financial Results
11. ANI Pharmaceuticals Announces an Agreement for the Development and Marketing of an Oral Soft Gel Prescription Product with Sofgen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Relmada Therapeutics, Inc., ... the treatment of chronic pain, announced today that it ... the position of  Senior Director of Clinical Development. ... James has established and led successful global clinical operations ... , to facilitate the clinical development of numerous therapeutics ...
(Date:9/18/2014)... , Sept. 18, 2014 /CNW/ - A new expert panel ... Canada , released today by the Council ... and effective medicines for children. Each year about half ... use at least one prescription drug. Much of this ... the authorized use), creating potential health risks. ...
(Date:9/18/2014)... MARLBOROUGH, Mass. , Sept. 18, 2014 ... RXII ), a biotechnology company focused on ... major unmet medical needs using RNA-targeted technologies, ... Executive Officer, Dr. Geert Cauwenbergh , ... Annual BioPharm America™ Conference on Wednesday, September ...
Breaking Medicine Technology:Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... of evaluable heavily-pretreated patients in the high dose ... tolerated overall.DALLAS, March 5 ACCESS PHARMACEUTICALS, ... safety and efficacy results from its Phase 2 ... heavily pretreated ovarian cancer patients. In this monotherapy ...
... March 4 A new study by researchers at ... essential B vitamins, including B6, B12, and folic acid, ... of the leading causes of vision loss among older ... key omega-3 fatty acids and phytosterols, are also contained ...
Cached Medicine Technology:Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 2Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 3Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 4Harvard Study Shows Folic Acid, B Vitamins in Animi-3(R) May Prevent Vision Loss 2
(Date:9/18/2014)... has proven it true: exercise is good for you. ... that exercise may have an added benefit for cancer ... mouse model of melanoma, found that combining exercise with ... Joseph Libonati, an associate professor in the School of ... Translational Nursing Research, was the senior author on the ...
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... 2014 Ben Quirk, CEO of Quirk ... Leadership Award by the Savannah Science Seminar in recognition ... throughout the nation and especially in Savannah. , “I ... Ben. “The Savannah Science Seminar is an amazing program ... generations have gone through the program,” he added. Eleventh ...
(Date:9/18/2014)... developed a new method to study Ebola virus in ... Conservation Society (WCS)-led research, published today in the journal ... of fecal samples from wild great apes to identify ... This represents a new tool for performing large, population-scale ... virus is studied and improve our understanding of the ...
(Date:9/18/2014)... The National Institutes of Health (NIH) recently awarded ... million grant to the Los Angeles Biomedical Research Institute ... of a vaccine to protect patients from the healthcare-related ... (MRSA). , The National Institute of Allergy ... grant to LA BioMed infectious disease specialists John E. ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... NY -- Vivian W. Pinn, MD will be awarded ... the 20th Annual Congress on Women,s Health, March 16-18, ... providers from across the country will gather at the ... advances in diagnosis and management, and innovative translational research ...
... rare in the United States but the third-leading cause of ... infections like chronic hepatitis, but the link is poorly understood. ... mechanism in mice that triggers inflammation in the liver and ... demonstrated in a mouse model that a particular micro-RNA (miR-124) ...
... , FRIDAY, Dec. 9 (HealthDay News) -- Depression and ... intensive care unit after treatment for a potentially deadly condition ... findings may also apply to ICU patients with other types ... machines, according to the researchers. "When people are discharged ...
... cells in the blood appears to have no relationship to ... breast cancer, according to new research from Fox Chase Cancer ... cells may signal that the disease has spread to other ... The results will be presented on Friday, December 9 ...
... DEC. 9, 2011] The investigation of a 2009 multistate ... an important cause of bacterial gastrointestinal illness, led to ... in Clinical Infectious Diseases and available ... recommendations for prevention, including a stronger message for consumers: ...
... Children who suffer from persistent or recurring chronic pain ... risk of developing internalizing symptoms such as anxiety, in response ... chronic pain in children and adolescents in 20 years, a ... from chronic pain and that girls suffer more frequently from ...
Cached Medicine News:Health News:Dr. Vivian W. Pinn to receive inaugural Bernadine Healy Award 2Health News:Researchers identify a novel therapeutic approach for liver cancer 2Health News:Depression, Disability Can Follow ICU Care: Study 2Health News:Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer 2Health News:Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer 3Health News:Ready-to-bake cookie dough not ready-to-eat, study of E. coli outbreak finds 2Health News:Chronic pain in children and adolescents becoming more common 2
Large image and wide angle design for transurethral examination and treatment of the ureter and renal pelvis....
High intensity lamp with built-in, switchable spare lamp. Low-noise fan with reduced air turbulence....
Calculate accurate growth percentiles and Z scores using the latest CDC growth charts....
PDA-version of the leading portable drug reference....
Medicine Products: